Warning letters, 483s, Recalls, Import Alerts, Audit observations
The USFDA has issued a Warning Letter to the Indian drug manufacturing facility of Patcos
The USFDA has classified Sun Pharma’s Baska (Halol) facility (FEI: 3002957541) as Official Action Indicated
An USFDA 483 to CDMO major Catalent’s Baltimore facility (FEI 3015558590) in US cite poor
FDA has published the USFDA Form 483 issued to sterile drug manufacturing facility of Fareva
Novo Nordisk’s Bloomington plant (FEI 3005949964, Catalent Indiana LLC) is classified OAI by USFDA in
FDA conducted an inspection at the Hetero Labs Ltd, Warehouse at Nakkapally Village, Vishakapatnam, Andra
In September 2025, the USFDA classified Sun Pharmaceutical Industries Ltd.’s Halol facility as OAI (Official
Novo Nordisk owned Catalent Indiana sterile products formulation facility was inspected by USFDA in June
USFDA 483 issued to Glenmark Pharma’s Pithampur facility (FEI: 3008565058) in India flagged critical deviations
FDA has published the USFDA Form 483 issued to Novo Nordisk API manufacturing facility at
